Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003357413 | Prostate | Tumor | response to testosterone | 17/3246 | 42/18723 | 3.45e-04 | 2.73e-03 | 17 |
GO:004269213 | Prostate | Tumor | muscle cell differentiation | 93/3246 | 384/18723 | 3.45e-04 | 2.73e-03 | 93 |
GO:001059413 | Prostate | Tumor | regulation of endothelial cell migration | 61/3246 | 232/18723 | 3.81e-04 | 2.96e-03 | 61 |
GO:004001313 | Prostate | Tumor | negative regulation of locomotion | 94/3246 | 391/18723 | 4.20e-04 | 3.21e-03 | 94 |
GO:001059513 | Prostate | Tumor | positive regulation of endothelial cell migration | 39/3246 | 133/18723 | 4.32e-04 | 3.30e-03 | 39 |
GO:190122211 | Prostate | Tumor | regulation of NIK/NF-kappaB signaling | 34/3246 | 112/18723 | 4.92e-04 | 3.64e-03 | 34 |
GO:003033613 | Prostate | Tumor | negative regulation of cell migration | 84/3246 | 344/18723 | 4.95e-04 | 3.66e-03 | 84 |
GO:005165119 | Prostate | Tumor | maintenance of location in cell | 56/3246 | 214/18723 | 7.31e-04 | 5.08e-03 | 56 |
GO:00456641 | Prostate | Tumor | regulation of neuron differentiation | 52/3246 | 196/18723 | 7.90e-04 | 5.38e-03 | 52 |
GO:00429211 | Prostate | Tumor | glucocorticoid receptor signaling pathway | 8/3246 | 14/18723 | 8.99e-04 | 5.96e-03 | 8 |
GO:00350511 | Prostate | Tumor | cardiocyte differentiation | 43/3246 | 156/18723 | 9.45e-04 | 6.20e-03 | 43 |
GO:005114614 | Prostate | Tumor | striated muscle cell differentiation | 69/3246 | 283/18723 | 1.56e-03 | 9.54e-03 | 69 |
GO:005123517 | Prostate | Tumor | maintenance of location | 78/3246 | 327/18723 | 1.56e-03 | 9.55e-03 | 78 |
GO:00319581 | Prostate | Tumor | corticosteroid receptor signaling pathway | 8/3246 | 15/18723 | 1.63e-03 | 9.79e-03 | 8 |
GO:009039811 | Prostate | Tumor | cellular senescence | 28/3246 | 93/18723 | 1.70e-03 | 1.01e-02 | 28 |
GO:003086613 | Prostate | Tumor | cortical actin cytoskeleton organization | 15/3246 | 40/18723 | 1.91e-03 | 1.11e-02 | 15 |
GO:003235515 | Prostate | Tumor | response to estradiol | 38/3246 | 141/18723 | 2.78e-03 | 1.52e-02 | 38 |
GO:006145011 | Prostate | Tumor | trophoblast cell migration | 8/3246 | 17/18723 | 4.45e-03 | 2.20e-02 | 8 |
GO:00487382 | Prostate | Tumor | cardiac muscle tissue development | 57/3246 | 236/18723 | 4.67e-03 | 2.29e-02 | 57 |
GO:00456651 | Prostate | Tumor | negative regulation of neuron differentiation | 21/3246 | 69/18723 | 5.29e-03 | 2.54e-02 | 21 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0414118 | Breast | Precancer | Protein processing in endoplasmic reticulum | 33/684 | 174/8465 | 2.78e-06 | 3.83e-05 | 2.94e-05 | 33 |
hsa0461218 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa0516918 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0414518 | Breast | Precancer | Phagosome | 27/684 | 152/8465 | 7.37e-05 | 6.85e-04 | 5.25e-04 | 27 |
hsa0516618 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
hsa0516316 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
hsa0414119 | Breast | Precancer | Protein processing in endoplasmic reticulum | 33/684 | 174/8465 | 2.78e-06 | 3.83e-05 | 2.94e-05 | 33 |
hsa0461219 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa0516919 | Breast | Precancer | Epstein-Barr virus infection | 35/684 | 202/8465 | 1.15e-05 | 1.26e-04 | 9.64e-05 | 35 |
hsa0414519 | Breast | Precancer | Phagosome | 27/684 | 152/8465 | 7.37e-05 | 6.85e-04 | 5.25e-04 | 27 |
hsa0516619 | Breast | Precancer | Human T-cell leukemia virus 1 infection | 33/684 | 222/8465 | 4.29e-04 | 3.31e-03 | 2.53e-03 | 33 |
hsa0516317 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
hsa0414522 | Breast | IDC | Phagosome | 34/867 | 152/8465 | 8.00e-06 | 9.99e-05 | 7.48e-05 | 34 |
hsa0516624 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
hsa0516324 | Breast | IDC | Human cytomegalovirus infection | 39/867 | 225/8465 | 6.66e-04 | 5.41e-03 | 4.05e-03 | 39 |
hsa0517014 | Breast | IDC | Human immunodeficiency virus 1 infection | 33/867 | 212/8465 | 9.28e-03 | 4.37e-02 | 3.27e-02 | 33 |
hsa0414532 | Breast | IDC | Phagosome | 34/867 | 152/8465 | 8.00e-06 | 9.99e-05 | 7.48e-05 | 34 |
hsa0516634 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
hsa0516334 | Breast | IDC | Human cytomegalovirus infection | 39/867 | 225/8465 | 6.66e-04 | 5.41e-03 | 4.05e-03 | 39 |
hsa0517015 | Breast | IDC | Human immunodeficiency virus 1 infection | 33/867 | 212/8465 | 9.28e-03 | 4.37e-02 | 3.27e-02 | 33 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CALR | insertion | Nonsense_Mutation | novel | c.1193_1194insCCAGATTCAAGCGATTCTCCTGCCTCGGCCTCCTGAGTAGCT | p.Glu398delinsAspGlnIleGlnAlaIleLeuLeuProArgProProGluTerLeu | p.E398delinsDQIQAILLPRPPE*L | P27797 | protein_coding | | | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
CALR | SNV | Missense_Mutation | | c.201N>C | p.Gln67His | p.Q67H | P27797 | protein_coding | deleterious(0.01) | benign(0.254) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
CALR | SNV | Missense_Mutation | | c.1167N>T | p.Glu389Asp | p.E389D | P27797 | protein_coding | tolerated(0.51) | benign(0) | TCGA-MY-A5BE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CALR | SNV | Missense_Mutation | | c.298G>C | p.Glu100Gln | p.E100Q | P27797 | protein_coding | deleterious(0.01) | benign(0.373) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CALR | insertion | In_Frame_Ins | novel | c.1114_1115insTTGTCA | p.Glu372delinsValValLys | p.E372delinsVVK | P27797 | protein_coding | | | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
CALR | SNV | Missense_Mutation | novel | c.308T>C | p.Ile103Thr | p.I103T | P27797 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CALR | SNV | Missense_Mutation | novel | c.193G>T | p.Gly65Cys | p.G65C | P27797 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
CALR | SNV | Missense_Mutation | | c.667N>A | p.Ala223Thr | p.A223T | P27797 | protein_coding | tolerated(0.38) | benign(0.228) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CALR | SNV | Missense_Mutation | rs746740154 | c.1231N>A | p.Gly411Ser | p.G411S | P27797 | protein_coding | tolerated_low_confidence(0.57) | benign(0.039) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
CALR | deletion | Frame_Shift_Del | | c.791delC | p.Pro264GlnfsTer2 | p.P264Qfs*2 | P27797 | protein_coding | | | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
811 | CALR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | RETINOIC ACID | | 9013706 |
811 | CALR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | OLTIPRAZ | OLTIPRAZ | 15961673 |
811 | CALR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | GENTAMICIN | GENTAMICIN | 15351734 |
811 | CALR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | GLUCOCORTICOID | | 8910610,8107808 |
811 | CALR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | ANTIANGIOGENIC | | 10498619 |
811 | CALR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | PEGINTERFERON ALFA-2A | | 26486786 |
811 | CALR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | Alpha 2 Interferon | | 26486786 |
811 | CALR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | VACCINIA VACCINE | | 15364449 |
811 | CALR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | RETINOID | | 9013706 |
811 | CALR | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, CLINICALLY ACTIONABLE, NUCLEAR HORMONE RECEPTOR, DRUGGABLE GENOME | | N/A | | 26697989,25873496,26071474,26449662 |